Gold nanoparticle layer: a promising platform for ultra-sensitive cancer detection

Area of Science:

• Biotechnology
• Nanotechnology
• Medical Diagnostics

Background:

• Early cancer detection is crucial for effective treatment and improved patient outcomes.
• Current diagnostic methods often lack the sensitivity required for detecting cancer at its earliest stages.
• Developing advanced biosensing platforms is essential for improving cancer diagnosis.

Purpose of the Study:

• To develop a novel gold nanoparticle layer (GNPL)-modified enzyme-linked immunosorbent assay (ELISA) plate for enhanced protein binding and activity.
• To evaluate the effectiveness of the GNPL-based ELISA for sensitive detection of cancer biomarkers.
• To assess the platform's potential for broad clinical applications in early cancer diagnosis.

Main Methods:

• A stable gold nanoparticle layer (GNPL) was prepared on a high-binding ELISA plate using chemical plating.
• The GNPL-modified ELISA plate was used for the detection of carcinoembryonic antigen (CEA), a representative cancer biomarker.
• The platform's performance was further validated using antithrombin detection.

Main Results:

• The GNPL-modified ELISA plate demonstrated superior protein binding efficiency while preserving protein activity.
• GNPL significantly amplified the ELISA signal, leading to a marked improvement in sensitivity.
• The limit of detection (LOD) for CEA was significantly lowered using the GNPL-based ELISA.
• The platform showed effectiveness and universality in detecting both CEA and antithrombin.

Conclusions:

• The developed GNPL-based ELISA platform offers a simple, low-cost, and highly sensitive method for biomarker detection.
• This technology holds significant promise for the early diagnosis of cancer in clinical settings.
• The GNPL platform's effectiveness and universality suggest its broad applicability in diagnostics.